Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma.

Trial Profile

Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2014

At a glance

  • Drugs Cintredekin besudotox (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 01 Jul 2007 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 01 Jul 2007 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 Nov 2006 11th Annual Meeting of the Society for Neuro-Oncology (SNO), November 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top